Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 11/20 | 0.35 |
| ▸ | CETP | P11597 | 5/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993413 | 0.88 | CETP (0.35) | IDH1CETPHCRTR1HCRTR2HRH4 | |
| SCHEMBL994666 | 0.88 | CETP (0.36) | IDH1CETPHCRTR1HCRTR2HRH4 | |
| SCHEMBL992310 | 0.86 | CETP (0.43) | CETP | |
| SCHEMBL995169 | 0.86 | CETP (0.40) | CETPHCRTR1HCRTR2 | |
| SCHEMBL993681 | 0.85 | CETP (0.36) | IDH1CETPHCRTR1HCRTR2HRH4 | |
| SCHEMBL1244525 | 0.81 | CETP (0.35) | IDH1CETPHCRTR1HCRTR2HRH4 | |
| SCHEMBL1896263 | 0.80 | SLC6A2 (0.50) | — | |
| SCHEMBL7782487 | 0.80 | SLC6A2 (0.38) | CETP | |
| SCHEMBL994074 | 0.80 | CETP (0.43) | CETP | |
| SCHEMBL995174 | 0.80 | SLC6A2 (0.51) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8389006-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389011-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | ABCB1, ABCG2, CYP3A7 | IDH1 4602/4885CETP 63/4885HCRTR1 4881/4885 |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | IDH1 2726/4885CETP 1/4885HCRTR1 4590/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | IDH1 2826/4885CETP 1214/4885HCRTR1 4651/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | IDH1 3778/4885CETP 1/4885HCRTR1 2553/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | IDH1 2819/4885CETP 162/4885HCRTR1 4825/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | IDH1 2020/4885CETP 485/4885HCRTR1 4822/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | IDH1 4734/4885CETP 1/4885HCRTR1 3009/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | IDH1 2144/4885CETP 227/4885HCRTR1 4809/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | IDH1 4486/4885CETP 1/4885HCRTR1 2669/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | IDH1 2144/4885CETP 227/4885HCRTR1 4809/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | IDH1 3778/4885CETP 1/4885HCRTR1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.